The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer

PI3K pathway alterations in cancer: variations on a theme

Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · see citing works

Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1.

Smiley, S. T., Reers, M., Mottola-Hartshorn, C., Lin, M., Chen, A. B., Smith, T. W., Steele, G., & Chen, L. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3671 · Cited by 1,629 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

The development of anticancer ruthenium( ii ) complexes: from single molecule compounds to nanomaterials

Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,020 · see citing works

The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 783 · see citing works

Signalling through phosphoinositide 3-kinases: the lipids take centre stage

Leevers, S. J., Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80029-5 · Cited by 678 · see citing works

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

Zhang, Y., Xia, M., Jin, K., Wang, S., Wei, H., Fan, C., Wu, Y., Li, X., Li, X., Li, G., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0796-y · Cited by 577 · see citing works

Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K

Courtnay, R., Ngo, D. C., Malik, N., Ververis, K., Tortorella, S. M., & Karagiannis, T. C. (2015) · Molecular Biology Reports · doi:10.1007/s11033-015-3858-x · Cited by 570 · see citing works

PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review)

Xie, Y., Shi, X., Sheng, K., Han, G., Li, W., Zhao, Q., Jiang, B., Feng, J., Li, J., & Gu, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9713 · Cited by 505 · see citing works

Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation

Kim, Y., & Chen, J. (2018) · Science · doi:10.1126/science.aar7389 · Cited by 456 · see citing works

PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation

Peltier, J., O'Neill, A., & Schaffer, D. V. (2007) · Developmental Neurobiology · doi:10.1002/dneu.20506 · Cited by 443 · see citing works

Energy metabolism in adult neural stem cell fate

Rafalski, V. A., & Brunet, A. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.10.007 · Cited by 280 · see citing works

PI3King the Lock: Targeting the PI3K/Akt/mTOR Pathway as a Novel Therapeutic Strategy in Neuroblastoma

King, D., Yeomanson, D., & Bryant, H. E. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000329 · Cited by 248 · see citing works

PI3K Signaling in Neurons: A Central Node for the Control of Multiple Functions

Sánchez‐Alegría, K., Flores‐León, M., Ávila-Muñoz, E., Rodríguez-Corona, N., & Arias, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123725 · Cited by 209 · see citing works

DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis

Xie, D., Gore, C., Zhou, J., Pong, R.-C., Zhang, H., Yu, L., Vessella, R. L., Wang, M., & Hsieh, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908458106 · Cited by 207 · see citing works

The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism

Qian, P., He, X., Paulson, A., Li, Z., Fang, T., Perry, J. M., Guo, F., Zhao, M. L., Zhi, L., Venkatraman, A., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.11.001 · Cited by 200 · see citing works

[37] Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells

Ambudkar, S. V. (1998) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(98)92039-0 · Cited by 199 · see citing works

Beclin 1, an Essential Component and Master Regulator of PI3K-III in Health and Disease

McKnight, N. C., & Yue, Z. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0028-5 · Cited by 187 · see citing works

Activity of any class IA PI3K isoform can sustain cell proliferation and survival

Foukas, L. C., Berenjeno, I. M., Gray, A., Khwaja, A., & Vanhaesebroeck, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906461107 · Cited by 166 · see citing works

SGK3 mediates INPP4B-dependent PI 3-Kinase signaling in breast cancer

Gasser, J. A., Inuzuka, H., Lau, A., Wei, W.-Y., Beroukhim, R., & Toker, A. (2014) · Molecules and Cells · doi:10.1016/j.molcel.2014.09.023 · Cited by 147 · see citing works

Critical role of PI3K signaling for NF-κB–dependent survival in a subset of activated B-cell–like diffuse large B-cell lymphoma cells

Kloo, B., Nagel, D., Pfeifer, M., Grau, M., Düwel, M., Vincendeau, M., Dörken, B., Lenz, P., Lenz, G., & Krappmann, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008969108 · Cited by 145 · see citing works

Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing

Guo, T., Feng, Y.-L., Xiao, J., Liu, Q., Sun, X., Xiang, J.-F., Kong, N., Liu, S., Chen, G., Wang, Y., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1518-x · Cited by 143 · see citing works

The PI3K, Metabolic, and Autophagy Networks: Interactive Partners in Cellular Health and Disease

Shanware, N. P., Bray, K., & Abraham, R. T. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134717 · Cited by 130 · see citing works

CRISPR–Cas ribonucleoprotein mediated homology-directed repair for efficient targeted genome editing in microalgae Nannochloropsis oceanica IMET1

Naduthodi, M. I. S., Mohanraju, P., Südfeld, C., D’Adamo, S., Barbosa, M. J., & John van der, O. O. S. T. (2019) · Biotechnology for Biofuels · doi:10.1186/s13068-019-1401-3 · Cited by 114 · see citing works

PM2.5-induced ADRB2 hypermethylation contributed to cardiac dysfunction through cardiomyocytes apoptosis via PI3K/Akt pathway

Yang, X., Zhao, T., Feng, L., Shi, Y., Jiang, J., Liang, S., Sun, B., Xu, Q., Duan, J., & Sun, Z. (2019) · Environment International · doi:10.1016/j.envint.2019.03.057 · Cited by 90 · see citing works

BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway

Yang, W., Wu, Z., Yang, K., Han, Y., Chen, Y., Zhao, W., Huang, F., Yao, J. Y., & Jin, W. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00487.2018 · Cited by 89 · see citing works

Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers

Baba, Y., Nosho, K., Shima, K., Hayashi, M., Meyerhardt, J. A., Chan, A. T., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2010) · Cancer · doi:10.1002/cncr.25630 · Cited by 86 · see citing works

Critical Role of PI3K/Akt/GSK3β in Motoneuron Specification from Human Neural Stem Cells in Response to FGF2 and EGF

Ojeda, L. D., Gao, J., Hooten, K. G., Wang, E., Thonhoff, J. R., Dunn, T. J., Gao, T., & Wu, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023414 · Cited by 75 · see citing works

Regulation and modulation of PTEN activity

Naderali, E., Khaki, A. A., Rad, J. S., Alihemmati, A., Rahmati, M., & Charoudeh, H. N. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4321-6 · Cited by 75 · see citing works

Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells

Gupta, P., Zhang, Y., Zhang, X., Wang, Y., Lu, K. W., Hall, T., Peng, R., Yang, D., Xie, N., & Chen, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487578 · Cited by 67 · see citing works

The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation

Cerniglia, G. J., Dey, S., Gallagher‐Colombo, S. M., Daurio, N. A., Tuttle, S. W., Busch, T. M., Lin, A., Sun, R. C., Esipova, T. V., Vinogradov, S. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0888 · Cited by 65 · see citing works

Mutational profiling of kinases in glioblastoma

Bleeker, F. E., Lamba, S., Zanon, C., Molenaar, R. J., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., Vandertop, W. P., Leenstra, S., Noorden, C. J. F. V., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-718 · Cited by 63 · see citing works

Natural product toosendanin reverses the resistance of human breast cancer cells to adriamycin as a novel PI3K inhibitor

Wang, K., Shan, Y., Ma, L., Kaiyong, Y., Baojin, H., Yin, W., Fang-zhou, Y., & Chen, Y. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.022 · Cited by 58 · see citing works

PTEN inhibition enhances neurite outgrowth in human embryonic stem cell–derived neuronal progenitor cells

Wyatt, L. A., Filbin, M. T., & Keirstead, H. S. (2014) · The Journal of Comparative Neurology · doi:10.1002/cne.23580 · Cited by 54 · see citing works

Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1

Wang, S., Liu, S., Zhao, B., Yang, F., Wang, Y.-T., Liang, Q., Sun, Y., Liu, Y., Song, Z., Cai, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4536 · Cited by 54 · see citing works

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

Tsuji, T., Ozasa, H., Aoki, W., Aburaya, S., Funazo, T. Y., Furugaki, K., Yoshimura, Y., Ajimizu, H., Okutani, R., Yasuda, Y., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0325 · Cited by 48 · see citing works

Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis

Lu, M., Hartmann, D., Braren, R., Gupta, A., Wang, B., Wang, Y., Mogler, C., Cheng, Z., Wirth, T., Friess, H., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6110-6 · Cited by 44 · see citing works

Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma

Höland, K., Boller, D., Hagel, C., Dolski, S., Treszl, A., Pardo, O. E., Ćwiek, P., Salm, F., Leni, Z., Shepherd, P. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094132 · Cited by 42 · see citing works

High doses of CRISPR/Cas9 ribonucleoprotein efficiently induce gene knockout with low mosaicism in the hydrozoan Clytia hemisphaerica through microhomology-mediated deletion

Momose, T., Cian, A. D., Shiba, K., Inaba, K., Giovannangeli, C., & Concordet, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-30188-0 · Cited by 42 · see citing works

Priming mobilization of hair follicle stem cells triggers permanent loss of regeneration after alkylating chemotherapy

Kim, J. Y., Ohn, J., Yoon, J.-S., Kang, B. M., Park, M., Kim, S., Lee, W., Hwang, S., Kim, J., Kim, K. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11665-0 · Cited by 41 · see citing works

EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway

Yan, X., Hui, Y., Hua, Y., Huang, L., Wang, L., Peng, F., Tang, C., Liu, D., Song, J., & Wang, F. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.125 · Cited by 38 · see citing works

Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202

Cheng, C., Liu, Z.-G., Zhang, H., Xie, J., Chen, X.-G., Zhao, X.-Q., Wang, F., Liang, Y.-J., Chen, L.-K., Singh, S., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2006714 · Cited by 37 · see citing works

PI3K/Akt/FoxO3a signaling mediates cardioprotection of FGF-2 against hydrogen peroxide-induced apoptosis in H9c2 cells

Liu, M., Li, G., Peng, L., Qu, S., Zhang, Y., Peng, J., Luo, X.-Y., Hu, H.-J., Ren, Z., Liu, Y., et al. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2658-5 · Cited by 36 · see citing works

Pyruvic acid/ethyl pyruvate inhibits melanogenesis in B16F10 melanoma cells through PI3K/AKT, GSK3β, and ROS‐ERK signaling pathways

Zhou, S., & Sakamoto, K. (2018) · Genes to Cells · doi:10.1111/gtc.12654 · Cited by 36 · see citing works

The Phenylethanol Glycoside Liposome Inhibits PDGF-Induced HSC Activation via Regulation of the FAK/PI3K/Akt Signaling Pathway

Zhang, S.-L., Ma, L., Zhao, J., You, S., Ma, X., Ye, X., & Liu, T. (2019) · Molecules · doi:10.3390/molecules24183282 · Cited by 35 · see citing works

Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase

Wu, C., Hsieh, Y., Hsiao, S.-H., Su, C.-Y., Li, Y., Huang, Y.-H., Huang, C., Hsieh, C., Yu, J., & Wu, Y. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00687 · Cited by 34 · see citing works

PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway

Wang, J., Sun, J. L., Zhang, N., Yang, R., Li, H., Zhang, Y., Chen, K., & Kong, D. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.054 · Cited by 31 · see citing works

Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling

Wang, L., Chen, B., Lin, M., Cao, Y., Chen, Y., Chen, X., Liu, T., & Hu, J. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.10.015 · Cited by 27 · see citing works

A cardiac glycoside HTF-1 isolated from Helleborus thibetanus Franch displays potent in vitro anti-cancer activity via caspase-9, MAPK and PI3K-Akt-mTOR pathways

Ma, L., Meng, Y., Tu, C., Cao, X., Wang, H., Li, Y., Man, S., Zhou, J., Li, M., Liu, Z., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.019 · Cited by 27 · see citing works

Overstimulation can create health problems due to increases in PI3K/Akt/GSK3 insensitivity and GSK3 activity

Liu, X. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-356 · Cited by 26 · see citing works

Activated PI3K Signaling as an Endogenous Inducer of p53 in Human Cancer

Lee, C. S., Kim, J.-S., & Waldman, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.4.3810 · Cited by 25 · see citing works

p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors

Fransson, S. M., Uv, A., Eriksson, H., Andersson, M. K., Wettergren, Y., Bergö, M. O., & Ejeskär, K. (2011) · Oncogene · doi:10.1038/onc.2011.492 · Cited by 25 · see citing works

3-Methyladenine can depress drug efflux transporters via blocking the PI3K–AKT–mTOR pathway thus sensitizing MDR cancer to chemotherapy

Zou, Z., Zhang, J., Zhang, H., Liu, H., Li, Z., Cheng, D., Chen, J., Liu, L., Ni, M., Zhang, Y. X., et al. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.936870 · Cited by 22 · see citing works

Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells

Wu, C., Murakami, M., Hsiao, S.-H., Chou, A.-W., Li, Y., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00277 · Cited by 21 · see citing works

Characterization and mechanism of phosphoinositide 3-kinases (PI3Ks) members in insulin-induced changes of protein metabolism in yellow catfish Pelteobagrus fulvidraco

Zhuo, M.-Q., Pan, Y., Wu, K., Xu, Y., & Luo, Z. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.04.002 · Cited by 18 · see citing works

1,25(OH)2 D3 attenuates indoxyl sulfate–induced epithelial-to-mesenchymal cell transition via inactivation of PI3K/Akt/β-catenin signaling in renal tubular epithelial cells

Chang, L.-C., Sun, H., Tsai, C.-H., Kuo, C., Liu, K., Lii, C., Huang, C., & Li, C. (2019) · Nutrition · doi:10.1016/j.nut.2019.110554 · Cited by 13 · see citing works

TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway

Wu, Y., Hu, Y., Yu, X., Zhang, Y., Huang, X., Chen, S., Li, Y., & Zeng, C. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.164 · Cited by 13 · see citing works

Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer

Li, S., Huang, C.-H., Lin, C., Huang, Z.-N., Chern, J., Lien, H., Wu, Y., Cheng, C.-H., Chang, C., & Chuu, J. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9337-2 · Cited by 11 · see citing works

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 416 · see citing works

Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 383 · see citing works

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

Zou, Y., Zheng, S., Xie, X., Ye, F., Hu, X., Tian, Z., Yang, L., Yang, L., Tang, Y., Tang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30217-7 · Cited by 227 · see citing works

Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)

Tian, Y., Lei, Y., Wang, Y., Lai, J., Wang, J., & Xia, F. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5567 · Cited by 211 · see citing works

The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions

Khezri, M. R., Jafari, R., Yousefi, K., & Zolbanin, N. M. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104787 · Cited by 135 · see citing works

Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity

Ashrafizadeh, M., Zarrabi, A., Hashemi, F., Zabolian, A., Saleki, H., Bagherian, M., Azami, N., Bejandi, A. K., Hushmandi, K., Ang, H. L., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111084 · Cited by 129 · see citing works

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

Vaghari‐Tabari, M., Hassanpour, P., Sadeghsoltani, F., Malakoti, F., Alemi, F., Qujeq, D., Asemi, Z., & Yousefi, B. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00348-2 · Cited by 137 · see citing works

Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer

Gu, J., Huang, W., Wang, X., Zhang, J., Tao, T., Zheng, Y., Liu, S., Yang, J., Chen, Z., Cai, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01587-9 · Cited by 113 · see citing works

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers

Zhang, L., Ye, B., Chen, Z., & Chen, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.002 · Cited by 110 · see citing works

Photoactivated DNA Nanodrugs Damage Mitochondria to Improve Gene Therapy for Reversing Chemoresistance

Wang, D., Yi, H., Geng, S., Jiang, C., Liu, J., Duan, J., Zhang, Z., Shi, J., Song, H., Guo, Z., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04002 · Cited by 76 · see citing works

Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)

Meng, D., He, W. A., Zhang, Y., Liang, Z., Zheng, J., Zhang, X., Zheng, X., Zhan, P., Chen, H., Li, W.-J., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105900 · Cited by 75 · see citing works

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells

Zhang, L., Li, Y., Hu, C., Chen, Y., Chen, Z., Chen, Z., Zhang, J., & Fang, S. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01524-w · Cited by 68 · see citing works

Recent advances in targeted drug delivery systems for resistant colorectal cancer

Sharifi-Azad, M., Fathi, M., Cho, W. C., Barzegari, A., Dadashi, H., Dadashpour, M., & Jahanban-Esfahlan, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02605-y · Cited by 65 · see citing works

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

Zhang, S., Peng, X., Li, X., Liu, H., Zhao, B., Elkabets, M., Liu, Y., Wang, W., Wang, R., Zhong, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03805-6 · Cited by 62 · see citing works

The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity

Chekmarev, J., Azad, M. G., & Richardson, D. R. (2021) · Cells · doi:10.3390/cells10092382 · Cited by 55 · see citing works

Nano-drug delivery system for the treatment of multidrug-resistant breast cancer: Current status and future perspectives

Gao, L., Meng, F., Yang, Z., Lafuente‐Merchan, M., Fernández, L. M., Cao, Y., Kusamori, K., Nishikawa, M., Itakura, S., Chen, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117327 · Cited by 54 · see citing works

The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity

Di, Y., Jing, X., Hu, K., Wen, X., Ye, L., Zhang, X., Qin, J., Ye, J., Lin, R., Wang, Z., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100909 · Cited by 53 · see citing works

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells

Feng, W., Zhang, M., Wu, Z., Wang, J., Dong, X.-D., Yang, Y., Teng, Q., Chen, X.-Y., Cui, Q., & Yang, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00955 · Cited by 51 · see citing works

PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN

Chong, X., Chen, J., Zheng, N., Zhou, Z., Hai, Y., Chen, S., Zhang, Y., Yu, Q., Yu, S., Chen, Z., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01531-x · Cited by 50 · see citing works

A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo

Liu, R.-M., Xu, P. H., Chen, Q., Feng, S., & Xie, Y. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153342 · Cited by 50 · see citing works

Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy

Choromańska, A., Chwiłkowska, A., Kulbacka, J., Baczyńska, D., Rembiałkowska, N., Szewczyk, A., Michel, O., Gajewska-Naryniecka, A., Przystupski, D., & Saczko, J. (2021) · Molecules · doi:10.3390/molecules26071850 · Cited by 50 · see citing works

Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy

Peng, X., Zhang, S., Jiao, W., Zhong, Z., Yang, Y., Claret, F. X., Elkabets, M., Wang, F., Wang, R., Zhong, Y., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02176-2 · Cited by 45 · see citing works

The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances

Khorasani, A. B. S., Hafezi, N., Sanaei, M., Jafari‐Raddani, F., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3998 · Cited by 45 · see citing works

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

Liang, X., Wang, Y., Shi, H., Dong, M., Han, H., & Li, Q. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s304526 · Cited by 41 · see citing works

Recent advances and future directions in anti‐tumor activity of cryptotanshinone: A mechanistic review

Ashrafizadeh, M., Zarrabi, A., Orouei, S., Saberifar, S., Salami, S., Hushmandi, K., & Najafi, M. (2020) · Phytotherapy Research · doi:10.1002/ptr.6815 · Cited by 42 · see citing works

Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling

Steelman, L. S., Chappell, W. H., Akula, S. M., Abrams, S. L., Cocco, L., Manzoli, L., Ratti, S., Martelli, A. M., Montalto, G., Cervello, M., et al. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100758 · Cited by 42 · see citing works

Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning

Mourragui, S. M. C., Loog, M., Vis, D. J., Moore, K., Manjón, A. G., van de Wiel, M. A., Reinders, M. J. T., & Wessels, L. F. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106682118 · Cited by 41 · see citing works

Harnessing bacterial immunity: CRISPR-Cas system as a versatile tool in combating pathogens and revolutionizing medicine

Al-Ouqaili, M. T. S., Ahmad, A., Jwair, N. A., & Al-Marzooq, F. I. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1588446 · Cited by 38 · see citing works

Novel Benzo Five-Membered Heterocycle Derivatives as P-Glycoprotein Inhibitors: Design, Synthesis, Molecular Docking, and Anti-Multidrug Resistance Activity

Yang, Z., Cai, Y., Yang, X., Li, Y., Wu, Q., Yu, Y., Chen, Z., Wei, B., Tian, J., Bao, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01999 · Cited by 37 · see citing works

Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells

Wu, Z., Yang, Y., Wang, G., Wang, J., Teng, Q., Sun, L., Lei, Z., Lin, L., Chen, Z., & Zou, C. (2020) · Cancer Science · doi:10.1111/cas.14505 · Cited by 37 · see citing works

Long noncoding RNAs have pivotal roles in chemoresistance of acute myeloid leukemia

Izadirad, M., Jafari, L., James, A. R., Unfried, J. P., Wu, Z., & Chen, Z. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.017 · Cited by 37 · see citing works

The Phenylethanol Glycoside Liposome Inhibits PDGF-Induced HSC Activation via Regulation of the FAK/PI3K/Akt Signaling Pathway

Zhang, S.-L., Ma, L., Zhao, J., You, S., Ma, X., Ye, X., & Liu, T. (2019) · Molecules · doi:10.3390/molecules24183282 · Cited by 35 · see citing works

Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

Yang, X., Wang, Y., Chen, S., Zhang, S., & Cui, C. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s332830 · Cited by 35 · see citing works

New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis

Sadrkhanloo, M., Paskeh, M. D. A., Hashemi, M., Raesi, R., Bahonar, A., Nakhaee, Z., Entezari, M., Goharrizi, M. A. S. B., Salimimoghadam, S., Ren, J. T., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154902 · Cited by 34 · see citing works

Epinephrine promotes breast cancer metastasis through a ubiquitin-specific peptidase 22–mediated lipolysis circuit

Zhou, Y., Chu, P., Wang, Y., Li, N., Gao, Q., Wang, S., Wei, J., Xue, G., Zhao, Y., Jia, H., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado1533 · Cited by 34 · see citing works

Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor

Wang, J., Teng, Q., Lei, Z., Ji, N., Cui, Q., Fu, H., Lin, L., Yang, D., Fan, Y., & Chen, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.601400 · Cited by 34 · see citing works

Heat Shock Protein 90 Triggers Multi-Drug Resistance of Ovarian Cancer via AKT/GSK3β/β-Catenin Signaling

Yin, L., Yang, Y., Zhu, W., Xian, Y., Han, Z., Huang, H., Peng, L., Zhang, K., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620907 · Cited by 34 · see citing works

DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer

Liu, M., Xu, C., Qin, X., Liu, W., Li, D., Jia, H., Gao, X., Wu, Y., Wu, Q., Xu, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873649 · Cited by 30 · see citing works

Antitumor Activity In Vivo and Vitro of New Chiral Derivatives of Baicalin and Induced Apoptosis via the PI3K/Akt Signaling Pathway

Hou, Y., Pi, C., Feng, X., Wang, Y., Fu, S., Zhang, X., Zhao, L., & Wei, Y. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.08.018 · Cited by 29 · see citing works

Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations

Chen, J. W., Murugesan, K., Newberg, J. Y., Sokol, E. S., Savage, H. M., Stout, T. J., Maund, S. L., & Hutchinson, K. E. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00341 · Cited by 26 · see citing works

pH-/Redox-Responsive Nanodroplet Combined with Ultrasound-Targeted Microbubble Destruction for the Targeted Treatment of Drug-Resistant Triple Negative Breast Cancer

Xiao, S., Guo, L., Chen, A., Shang, M., Shi, D., Meng, D., Sun, X. Y., Wang, X., Liu, R., Zhao, Y., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c20478 · Cited by 25 · see citing works

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

Wu, Z., Teng, Q., Yang, Y., Acharekar, N., Wang, J., He, M. Y., Yoganathan, S., Lin, J., Wang, J., & Chen, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.018 · Cited by 25 · see citing works

PSMA‐Targeted Nanoparticles with PI3K/mTOR Dual Inhibitor Downregulate P‐Glycoprotein and Inactivate Myeloid‐Derived Suppressor Cells for Enhanced Chemotherapy and Immunotherapy in Prostate Cancer

Yin, L., Yang, F., Wang, W., Zhang, L., Cao, Z., Shi, H., Pan, K.-H., Wu, L., Xiao, H., & Xing, N. (2025) · Advanced Materials · doi:10.1002/adma.202415322 · Cited by 24 · see citing works

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Hussen, B. M., Najmadden, Z. B., Abdullah, S. R., Rasul, M. F., Mustafa, S. A., Ghafouri‐Fard, S., & Taheri, M. N. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01713-8 · Cited by 27 · see citing works

Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription

Oh, S., Lee, K. W., Madhi, H., Jeong, J.-W., Park, S., Kim, M.-J., Lee, Y., Han, H.-T., Hwangbo, C., Yoo, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051710 · Cited by 23 · see citing works

The Expression Regulatory Network in the Lung Tissue of Tibetan Pigs Provides Insight Into Hypoxia-Sensitive Pathways in High-Altitude Hypoxia

Yang, Y., Yuan, H., Yang, T., Li, Y., Gao, C., Jiao, T., Cai, Y., & Zhao, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.691592 · Cited by 23 · see citing works

Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies

Dong, X., Zhang, M., Teng, Q., Lei, Z., Cai, C., Wang, J., Wu, Z., Yang, Y., Chen, X., Guo, H., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217309 · Cited by 22 · see citing works

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter

Fu, H., Wu, Z., Lei, Z., Teng, Q., Yang, Y., Ashby, C. R., Lei, Y., Lian, Y., & Chen, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.861642 · Cited by 21 · see citing works

The prevention of multi-drug resistance in cancers through the application of nanotechnology-based targeted delivery systems for combination therapies involving traditional Chinese medicine

Abdullah, S., Mukherjee, S., ., S., & Debnath, B. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100386 · Cited by 22 · see citing works

Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis

Zhang, L., Lin, Y., Li, H., Wang, Y., Hu, C., Shangguan, X.-Y., Tang, S., Chen, J., Hu, P., Chen, Z., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02253-6 · Cited by 20 · see citing works

Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation

de Godoy, B. L. V., Moschetta‐Pinheiro, M. G., Chuffa, L. G. D. A., Ponde, N. F., Reiter, R. J., Colombo, J., & Zuccari, D. A. P. D. C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121708 · Cited by 20 · see citing works

Lower SLC7A2 expression is associated with enhanced multidrug resistance, less immune infiltrates and worse prognosis of NSCLC

Jiang, S., Zou, J., Dong, J., Shi, H., Chen, J., Li, Y., Duan, X., & Li, W. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-022-01023-x · Cited by 19 · see citing works

A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency

Lin, R., Zhang, L., Ye, B., Wang, Y., Li, Y.-D., Jason, H., Liu, W., Hu, P., Chen, J., Chen, Z., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216181 · Cited by 18 · see citing works

Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer

Hong, Y. C., He, J., Deng, D., Liu, Q., Zu, X., & Shen, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06367-9 · Cited by 19 · see citing works

Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer

Mahapatra, E., Sengupta, D., Kumar, R., Dehury, B., Das, S., Roy, M., & Mukherjee, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.803114 · Cited by 16 · see citing works

Aptamer functionalized hypoxia-potentiating agent and hypoxia-inducible factor inhibitor combined with hypoxia-activated prodrug for enhanced tumor therapy

Ma, Y., Zhang, H., Shen, X., Yang, X., Deng, Y. P., Tian, Y., Chen, Z., Pan, Y., Luo, H., Zhong, C., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217102 · Cited by 16 · see citing works

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

Huang, L., Liao, Z., Liu, Z., Chen, Y., Huang, T., & Xiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900825 · Cited by 16 · see citing works

Strategies for overcoming ABC transporter-mediated multidrug resistance in colorectal cancer

de Groot, R. A., Reedijk, D., Faucher, Q., Mihaila, S. M., & Masereeuw, R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00412.2025 · Cited by 15 · see citing works

The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter

Narayanan, S., Gujarati, N. A., Wang, J., Wu, Z., Koya, J., Cui, Q., Korlipara, V. L., Ashby, C. R., & Chen, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052463 · Cited by 15 · see citing works

Self-assembled multicomponent prodrugs with GSH/ROS site-responsiveness enable spatiotemporally controlled release for treating resistant NSCLC

Zhang, C., Chen, Y., Shi, X., Liu, Y., Zhou, J., Leng, L., Zhang, T., Liu, S., Liu, J., Wang, T., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114654 · Cited by 14 · see citing works

Lycium barbarum polysaccharide reverses drug resistance in oxaliplatin-resistant colon cancer cells by inhibiting PI3K/AKT-dependent phosphomannose isomerase

Ma, L., Ai, F., Xiao, H., Wang, F., Shi, L., Bai, X., Zhu, Y., & Ma, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1367747 · Cited by 14 · see citing works

Siteng Fang Reverses Multidrug Resistance in Gastric Cancer: A Network Pharmacology and Molecular Docking Study

Guo, L., Shi, H., & Zhu, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671382 · Cited by 14 · see citing works

Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer

Song, D., Guo, M., Wu, K., Hao, J., Nie, Y., & Fan, D. (2021) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmab101 · Cited by 13 · see citing works

Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma

Yin, X., Rong, J., Shao, M., Zhang, S., Yin, L., He, Z., & Wang, X. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02486-5 · Cited by 13 · see citing works

Downregulation of PIK3CB Involved in Alzheimer’s Disease via Apoptosis, Axon Guidance, and FoxO Signaling Pathway

Zhou, Z., Bai, J., Zhong, S., Zhang, R., Kang, K., Zhang, X., Xu, Y., Zhao, C., & Zhao, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1260161 · Cited by 12 · see citing works

Potential biomarkers for retinopathy of prematurity identified by circular RNA profiling in peripheral blood mononuclear cells

Li, Y., Zhou, H., Huang, Q., Tan, W., Cai, Y., Wang, Z., Zou, J., Li, B., Yoshida, S., & Zhou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953812 · Cited by 12 · see citing works

Targeting Cardiac Metabolic Pathways: A Role in Ischemic Management

Yehualashet, A. S., Belachew, T. F., Kifle, Z. D., & Abebe, A. M. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s264130 · Cited by 12 · see citing works

Epigenetic regulation of stem cells in lung cancer oncogenesis and therapy resistance

Wu, J., Feng, J., Zhang, Q., He, Y., Xu, C. S., Wang, C., & Li, W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1120815 · Cited by 11 · see citing works

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment

Zheng, L. T., Chang, R., Liang, B., Wang, Y., Zhu, Y., Jia, Z., Fan, J., Zhang, Z., Du, B., & Kong, D. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.107 · Cited by 11 · see citing works

Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells

Zhang, L., Ye, B., Lin, Y., Li, Y.-D., Wang, J., Chen, Z., Ping, F., & Chen, Z.-S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.867128 · Cited by 11 · see citing works

Ginsenoside Rg3 combined with near‐infrared photothermal reversal of multidrug resistance in breast cancer MCF‐7/ADR cells

Chang, Y., Fu, Q., Lu, Z., Jin, Q., Jin, T., & Zhang, M. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4205 · Cited by 10 · see citing works

The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer

Hu, X., Lei, X., Guo, J., Fu, W., Sun, W. Y., Lu, Q., Su, W., Xu, Q., & Tu, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.927640 · Cited by 10 · see citing works

VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study

Narayanan, S., Fan, Y., Gujarati, N. A., Teng, Q., Wang, J., Cai, C., Yang, Y., Chintalapati, A. J., Lei, Y., Korlipara, V. L., et al. (2021) · Cancers · doi:10.3390/cancers13184675 · Cited by 10 · see citing works

Development and validation of a small extracellular vesicle-derived RNA signature for early diagnosis of lung adenocarcinoma and prognosis in advanced stages

Meng, R., Gao, Y., Peng, Z. Q., Chen, H., Li, Y., Liu, Y., Shen, L., Pan, H., Zheng, L., Cheng, D., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02524-2 · Cited by 9 · see citing works

Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity

Alves, E., McLeish, E., Blancafort, P., Coudert, J. D., & Gaudieri, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.712722 · Cited by 9 · see citing works

[Lung Cancer Stem-like Cells and Drug Resistance].

Pan, Z., Liu, H., & Chen, J. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.02 · Cited by 9 · see citing works

FDA approved fused-pyrimidines as potential PI3K inhibitors: a computational repurposing approach

Vishwakarma, P., Siddiqui, N. F., Thakur, S., & Jadhav, H. R. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2276315 · Cited by 9 · see citing works

Applications and advancements of CRISPR-Cas in the treatment of lung cancer

Pan, L., Ju, Y., Peng, F., & Luo, J. D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1295084 · Cited by 11 · see citing works

Downregulation of miRNA-14669 Reverses Vincristine Resistance in Colorectal Cancer Cells through PI3K/AKT Signaling Pathway

Wang, T., Dong, W.-H., Wang, F., Liu, Q., Yang, Y., Guo, P., Li, X., & Wei, B. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210806154225 · Cited by 9 · see citing works

Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer

Yan, B., Shi, R., Lu, Y.-Y., Fang, D.-D., Ye, M., & Zhou, Q. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279752 · Cited by 9 · see citing works

PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma

Cao, J., Zeng, K., Chen, Q., Yang, T., Lu, F., Lin, C., Zhan, J., Ma, W., Zhou, T., Huang, Y., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06615-8 · Cited by 9 · see citing works

Study of the PI3K /Akt/ mTOR signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA‐MB ‐231

Liu, X., Liu, J., Yan, B., Quan, Z., Wang, X., Ma, Y., Alarfaj, A. A., & Yan, L. (2023) · Environmental Toxicology · doi:10.1002/tox.23981 · Cited by 8 · see citing works

Double Swords in One: Novel Selective PI3 K /110β PROTAC Degraders for the Treatment of Multidrug-Resistant Cancer by Activating ERS and Inhibiting P-gp

Cen, J., Lu, P., Wang, C., Wu, J., Hu, X., Zhao, H., Li, M., Luo, M., Zhao, S., Li, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03169 · Cited by 7 · see citing works

Synthesis and in vitro anticancer evaluation of novel flavonoid-based amide derivatives as regulators of the PI3K/AKT signal pathway for TNBC treatment

Zha, D., Li, Y., Luo, Y., Liu, Y., Lin, Z., Lin, C., Chen, S., Wu, J., Yu, L., Chen, S., et al. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00148a · Cited by 7 · see citing works

Application of CRISPR/Cas9 System to Reverse ABC-Mediated Multidrug Resistance

Wang, W., Liang, Z., Ma, P., Zhao, Q., Dai, M., Zhu, J., Xu, H., Xu, H., Chang, Q., & Zhen, Y. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00627 · Cited by 7 · see citing works

Predicting clinical drug response from model systems by non-linear subspace-based transfer learningPreprint

Mourragui, S. M. C., Loog, M., Vis, D. J., Moore, K., Manjón, A. G., van de Wiel, M. A., Reinders, M. J. T., & Wessels, L. F. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.177139 · Cited by 7 · see citing works

Tumor microenvironment‐responsive drug self‐delivery systems to treat cancer and overcome MDR

Li, L., Xie, Y.-P., Qin, Y., Chu, H.-P., Xie, H., Zang, D., & Liu, T. (2024) · Rare Metals · doi:10.1007/s12598-024-02892-6 · Cited by 6 · see citing works

Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors

Garcia, A. R., Mendes, A., Custódia, C., Faria, C. C., Barata, J. T., Malhó, R., Figueira, I., & Brito, M. A. (2023) · Cancers · doi:10.3390/cancers15153973 · Cited by 6 · see citing works

Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy

Raza, M., Kumar, N., Nair, U., Luthra, G., Bhattacharyya, U., Jayasundar, S., Jayasundar, R., & Sehrawat, S. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04149-7 · Cited by 6 · see citing works

Biological significance of extracellular vesicles in innate immune system

Jadamba, B., Park, J., & Lee, H. (2025) · Innate Immunity · doi:10.1177/17534259251355029 · Cited by 5 · see citing works

Meta‐analysis of microarray data to determine gene indicators involved in the cisplatin resistance in ovarian cancer

Sheikhshabani, S. H., Amini‐Farsani, Z., Kazemifard, N., Modarres, P., Farsani, Z. A., Omrani, M. D., & Ghafouri‐Fard, S. (2023) · Cancer Reports · doi:10.1002/cnr2.1884 · Cited by 5 · see citing works

Molecular Mechanisms of Breast Cancer Drug Resistance and CRISPR/Cas9 Strategies to Overcome

Hussen, B. M., Ismael, B. S., Abdulla, S. S., Jamal, N. H., Mustafa, S. A., Najmalddin, Z. B., & Rasul, M. F. (2024) · BioMed Target Journal · doi:10.59786/bmtj.221 · Cited by 4 · see citing works

Mitochondrial-Targeting Zwitterionic Nanomedicine Based on Tertiary Amine N ‑oxide Polymers for Triple-Negative Breast Cancer Therapy

Huang, Y., Zhu, W., Zhang, J., Zhang, Y., Liu, Y., Wang, G., & Yang, W. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c01461 · Cited by 4 · see citing works

Unraveling the Mechanism of Curculiginis Rhizoma in Suppressing Cisplatin Resistance in Non-Small Cell Lung Cancer: An Experimental Study

Huang, X., Wang, M., Zhu, B., Yu, H., Gao, R., Liu, W., Cheng, J., Hua, G., & Xue, C.-M. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s448636 · Cited by 3 · see citing works

Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations

Zhang, M., She, M., Chen, J., Zeng, X.-Q., Xiong, Q.-Q., Cen, Y.-H., Ye, J.-A., Qiu, G., Yang, S.-Y., & Ren, G.-H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117603 · Cited by 3 · see citing works

Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor

Liu, B., Lu, Y., Lin, R., Xu, J., Shang, Z., Hou, X., Shao, X., Pan, Z., Yu, T., & Feng, W. (2025) · BMC Cancer · doi:10.1186/s12885-024-13371-7 · Cited by 3 · see citing works

Multifunctional amino acid-based nanoparticles for sequential drug delivery to overcome multidrug resistant cancer

Wang, T., Sang, N., Ménard‐Moyon, C., Miyako, E., & Bianco, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114954 · Cited by 3 · see citing works

4′-Demethylpodophyllotoxin functions as a mechanism-driven therapy by targeting the PI3K-AKT pathway in Colorectal cancer

Liu, J., Luo, D., Chen, X., Liu, J., Chen, J., Shi, M., Dong, H., Xu, Y., Wang, X., Yu, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102199 · Cited by 3 · see citing works

Optimization of IgG1 immune complexes to stimulate cytokine production in innate cells

Deb, A., Lott, K., Miceli, A., & Kaplan, B. L. F. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113851 · Cited by 3 · see citing works

MOESM2 of The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer

Zhang, L., Li, Y., Wang, Q., Chen, Z., Li, X., Wu, Z., Hu, C., Liao, D., Zhang, W., & Chen, Z.-S. (2020) · Figshare · doi:10.6084/m9.figshare.11643636

A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency

Lin, R., Zhang, L., Ye, B., Wang, Y., Li, Y.-D., Jason, H., Liu, W., Hu, P., Chen, J., Chen, Z., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216181 · Cited by 18 · see citing works

MOESM1 of The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer

Zhang, L., Li, Y., Wang, Q., Chen, Z., Li, X., Wu, Z., Hu, C., Liao, D., Zhang, W., & Chen, Z.-S. (2020) · Figshare · doi:10.6084/m9.figshare.11643627

MOESM3 of The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer

Zhang, L., Li, Y., Wang, Q., Chen, Z., Li, X., Wu, Z., Hu, C., Liao, D., Zhang, W., & Chen, Z.-S. (2020) · Figshare · doi:10.6084/m9.figshare.11643645

MOESM4 of The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer

Zhang, L., Li, Y., Wang, Q., Chen, Z., Li, X., Wu, Z., Hu, C., Liao, D., Zhang, W., & Chen, Z.-S. (2020) · Figshare · doi:10.6084/m9.figshare.11643651